The two are deliberately not reconciled. The Charter forecasts, the RAID Log warns, the Conditions Register flags GC-03 as at risk. This document records what those forecasts and warnings turned out to be worth. Making the earlier documents agree with this one retrospectively would destroy the only thing that makes a governance record valuable.
Vitalis Therapeutics Inc. — The Gate 6 closure review for VitaFlow (VTX-401): pivotal results against the target product profile, approval and label outcome, the first eight months of commercial performance against plan, final program accounting, and the lessons recorded at closure. Window to 30 June 2030.
1. Outcome
| Milestone | Planned | Actual | Variance |
|---|---|---|---|
| NDA submission (Gate 5) | 30 Sep 2028 | 12 Oct 2028 | on schedule |
| Filing acceptance | 60 days from submission | 11 Dec 2028 | accepted |
| Approval (Gate 6) | 11 Oct 2029 | 05 Oct 2029 | PDUFA met |
| First commercial shipment | 01 Nov 2029 | 01 Nov 2029 | on plan |
| Final program cost | $243,040,000 ceiling | $238,600,000 | $4,440,000 under |
VitaFlow was approved on 05 October 2029 and launched on 01 November 2029, on the dates set at Gate 4 three years earlier, and $4,440,000 under a ceiling authorized at charter. On schedule and cost, this program delivered.
2. Gate 5 — Pivotal Results
Gate 5 held 30 September 2028, outcome GO (5-0). Both pivotal trials met their co-primary endpoints; the NDA was submitted twelve days later.
| Endpoint | Result | TPP position | Assessment |
|---|---|---|---|
| Pivotal 301 — mean weight reduction, week 68 | 14.2% | ≥15% target / ≥10% min | below target, clears minimum |
| Pivotal 302 — mean weight reduction, week 68 | 14.8% | ≥15% target / ≥10% min | below target, clears minimum |
| Responder rate ≥5%, pooled | 81.3% | ≥80% target | met |
| Responder rate ≥10%, pooled | 64.1% | hierarchical secondary | met |
| Responder rate ≥15%, pooled | 41.7% | hierarchical secondary | met |
| Waist circumference change | −11.4 cm | hierarchical secondary | met |
| GI-attributed discontinuation | 6.4% | ≤4% target / ≤7% min | below target, inside minimum |
| CV sub-study — MACE hazard ratio | 0.91 (UB 1.18) | UB <1.4 | met |
Weight reduction came in at 14.2% and 14.8% — below the ≥15% target, comfortably above the ≥10% minimum. That was always the expected shape: the Target Product Profile never claimed leadership on magnitude.
GI-attributed discontinuation came in at 6.4%, against a ≤4% target and a ≤7% minimum. It cleared the bar that made the product worth launching and missed the bar that would have made it differentiated. Phase 2 had delivered 5.1% at 36 weeks; over 68 weeks and across 2,480 participants, the separation narrowed.
3. What Happened to the Differentiation Thesis
From Gate 0 onward this program had one commercial argument: tolerability at an efficacious dose. Not more weight loss — better tolerated weight loss. Every design decision traced to it, including the deliberately wide Phase 2 dose span and the concession of the dosing-interval target at TPP v3.0.
At Gate 6 the label was granted for the full population sought, with class labeling and no REMS. Then:
- Class boxed warning for thyroid C-cell tumors carried, as planned (D-07).
- No REMS required — the position held.
- Indication granted for BMI ≥30, or ≥27 with at least one comorbidity — the full population sought.
- Tolerability language in Section 6 is descriptive. No comparative tolerability claim was granted, which is the commercially significant outcome.
The Phase 3 Protocol Summary §4 records the position at the time: the GI-discontinuation endpoint sat fourth in the testing hierarchy, behind three weight-reduction endpoints, because agency expectations for the indication drive weight endpoints to the top and reordering to protect a commercial claim would have been visible as exactly that. The program argued the point at protocol finalization and lost.
It was the right call on the regulatory merits and it cost the commercial thesis. Both things are true, and a review that recorded only one of them would be useless.
4. Commercial Performance — First Two Quarters
Window 01 Nov 2029 to 30 Jun 2030.
| Measure | Plan | Actual | Variance |
|---|---|---|---|
| Net revenue | $118,000,000 | $91,400,000 | -22.5% |
| Patients on therapy | 14,200 | 11,600 | -18.3% |
| Covered lives | 62% | 44% | -18% pts |
| Net price per patient year | $12,500 | $11,050 | -11.6% |
| Six-month persistence | — | 71% | no plan comparator |
Revenue landed 23% below plan. The decomposition matters more than the headline: patients on therapy were 18% light and net price was 12% light, and both trace to the same cause.
GC-03 was issued at Gate 4 because market access evidence had been scoped but not started. It was reported at risk at the 15 October 2026 status date, with two of five payer advisory boards unscheduled. It closed late. Payer negotiations that should have opened on a completed evidence package opened on a partial one, and without a comparative tolerability claim in the label (§3) there was less to negotiate with.
Two governance failures compounded: the evidence work started late, and the claim that would have carried the negotiation was never won.
Against the 15.0% hurdle, the program's return will now depend on coverage expansion over the remaining forecast horizon rather than on the launch trajectory. That assessment belongs to a benefits realization review, not to this document.
5. Final Program Accounting
| Component | Amount |
|---|---|
| Authorized ceiling | $243,040,000 |
| Base program | $217,000,000 |
| Contingency drawn | $22,400,000 |
| Final program cost | $238,600,000 |
| Under ceiling | $4,440,000 |
| Contingency remaining at closure | $3,640,000 |
Contingency draws after the status date
| Ref | Draw | Amount | Approved |
|---|---|---|---|
| CD-03 | Phase 3 enrolment recovery — 34 additional sites | $4,900,000 | 18 Feb 2027 |
| CD-04 | Pre-approval inspection remediation at Aldergate | $1,850,000 | 02 Mar 2029 |
| CD-05 | Launch supply build ahead of approval | $6,400,000 | 22 Jan 2029 |
Total drawn across the program was $22,400,000 of the $26,040,000 reserve — 86%. At the 15 October 2026 status date the Contingency Register showed $9,050,000 drawn and observed that the realistic question was not whether more would be drawn but whether what remained was adequate. It was, with $3,640,000 unused.
6. Pre-Approval Inspection
Conducted 12 June 2029 at Aldergate Biologics. 1 Form 483 observation.
One Form 483 observation at Aldergate concerning environmental monitoring documentation. Responded within 15 working days; closed before the action date.
Worth noting against the record: R-07 anticipated an inspection finding and rated it Low. The mitigation recorded in the RAID Log — two internal audits ahead of the inspection window and QA embedded on site from registration batches — was executed. A single documentation observation on a first inspection of a contract site is a good outcome, and it is one of the few places in this program where a risk was correctly rated, correctly mitigated, and behaved as predicted.
7. Lessons Recorded at Closure
L-01 — Technical transfer between organizations is a risk, not an execution task
I-02 cost $1,850,000 and a gate condition, and appeared on no risk register beforehand. The signal was available at Gate 1, where analytical method qualification scored at threshold and was noted but not carried forward.
L-02 — Market access evidence must start when Phase 3 starts, not when Phase 3 reads out
GC-03 was issued at Gate 4 because the payer evidence plan was still a plan three years into the program. It closed late, and coverage at launch reached 44% of lives against a 62% assumption — the single largest contributor to the revenue shortfall.
L-03 — A differentiation claim that is not a primary endpoint may not survive to the label
GI-attributed discontinuation was the entire differentiation thesis and sat fourth in the testing hierarchy. It cleared the minimum acceptable position but missed target, and the approved label carries no comparative tolerability claim.
L-04 — The abstention was the most valuable thing said at Gate 4
The CFO abstained on un-refreshed gross-to-net assumptions. Actual net price at launch was $11,050 against a $12,500 assumption.
L-05 — The gate structure worked
Every tranche was released against evidence, no stage was funded before its gate carried, and the program closed $4,440,000 under a ceiling set three years before approval.
8. What the Governance Record Was Worth
The suite made a set of claims about how gated governance protects a program. This is the scorecard.
| Claim | Outcome |
|---|---|
| Tranche release prevents over-commitment | held — no stage funded before its gate carried; closed $4,440,000 under ceiling |
| Gates placed where information arrives | held — Gate 4 sat after the End-of-Phase-2 meeting and the Phase 3 authorization was taken on the agency’s known position |
| Conditions convert weak positions into dated obligations | partial — GC-01 closed and worked; GC-03 closed late and the underlying gap reached the market |
| Verification methods fixed at issue | held — no method was renegotiated; GC-03 was not closed on scheduling in place of attendance |
| Must-meets are not outvotable | held — never tested, because no must-meet failed |
| Abstentions carry information | held — the CFO’s Gate 4 abstention on gross-to-net preceded a net price 12% below plan |
| The RAID log names the real exposure | partial — R-06 correctly named payer coverage; I-02 was never a risk before it was an issue |
It did not make the molecule more differentiated than it was, and it did not force the market access work to start on time — it only recorded, clearly and in advance, that the work was late. A governance system converts unknown problems into known ones. Acting on the known ones is a management decision, and this program made that decision late on the one that mattered most.
Both of the things that underperformed at launch — the differentiation margin and payer coverage — were visible in writing at the 15 October 2026 status date, more than two and a half years earlier. That is the strongest argument for the record, and the sharpest criticism of the program that kept it.